(OZEM) Roundhill GLP-1 Weight Loss - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • • Health
OZEM: GLP-1, Weight Loss, Pharmaceuticals, Biotechnology, Healthcare
The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is a non-diversified exchange-traded fund that primarily targets companies involved in GLP-1 (Glucagon-Like Peptide-1) therapies and weight loss treatments. The funds manager allocates at least 80% of its net assets (including borrowings for investment purposes) to equity securities of relevant companies or derivative instruments tied to these firms, such as swap agreements or forward contracts. This focus allows the fund to capture growth opportunities in the rapidly evolving GLP-1 and weight loss pharmaceutical sectors.
From a technical standpoint, OZEM has shown a SMA 20 of 25.46, slightly above its current price of 25.42, indicating near-term stability. The SMA 50 at 24.76 suggests recent upward momentum, while the SMA 200 at 26.50 reflects longer-term equilibrium. The ATR of 0.39 signals moderate volatility, with average daily price swings remaining contained. The funds average 20-day volume of 14,280 shares highlights moderate liquidity, which may impact trading efficiency during high-volume periods.
Fundamentally, OZEM manages an AUM of $40.59 million, positioning it as a smaller ETF in its category. This size allows for targeted exposure to niche biotech and pharmaceutical companies specializing in GLP-1 receptor agonists and weight loss therapies. The funds non-diversified nature increases its vulnerability to sector-specific risks but also enables concentrated exposure to high-growth potential in the obesity and diabetes treatment markets.
3-Month Forecast: Based on the providedOn the technical side, if OZEM breaks above its SMA 200 at $26.50, it may signal a bullish trend, potentially driving the price toward $27.50. Conversely, a drop below $24.76 could trigger a bearish correction, testing the $24.00 level. The moderate average volume of 14,280 shares may lead to occasional price gaps during high-impact news events.
Fundamentally, the AUM of $40.59 million suggests that OZEM remains a niche ETF with limited institutional interest. However, positive clinical trial results or FDA approvals for GLP-1 therapies could drive inflows, potentially increasing AUM and reducing liquidity risks. Conversely, regulatory setbacks or market competition could weigh on the funds performance.
Overall, OZEM is expected to remain range-bound with limited upside unless sector-specific catalysts emerge. Investors should monitor SMA crossovers and AUM trends for signals of shifting market sentiment.Additional Sources for OZEM ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
OZEM ETF Overview
| Market Cap in USD | 40m |
| Category | Health |
| TER | 0.59% |
| IPO / Inception | 2024-05-20 |
OZEM ETF Ratings
| Growth 5y | -27.3% |
| Fundamental | - |
| Dividend | 7.29% |
| Rel. Strength Industry | -8.01 |
| Analysts | - |
| Fair Price Momentum | 21.52 USD |
| Fair Price DCF | - |
OZEM Dividends
| Dividend Yield 12m | 0.21% |
| Yield on Cost 5y | 0.21% |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 100.0% |
OZEM Growth Ratios
| Growth Correlation 3m | 6.1% |
| Growth Correlation 12m | -43.2% |
| Growth Correlation 5y | -43.2% |
| CAGR 5y | -5.04% |
| CAGR/Max DD 5y | -0.25 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | -13.15 |
| Beta | 0.97 |
| Volatility | 29.72% |
| Current Volume | 11.6k |
| Average Volume 20d | 8.8k |
As of March 14, 2025, the stock is trading at USD 24.04 with a total of 11,600 shares traded.
Over the past week, the price has changed by -5.43%, over one month by -4.07%, over three months by -7.94% and over the past year by -5.04%.
Probably not. Based on ValueRay Analyses, Roundhill GLP-1 Weight Loss (NASDAQ:OZEM) is currently (March 2025) not a good stock to buy. It has a ValueRay Growth Rating of -27.30 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of OZEM as of March 2025 is 21.52. This means that OZEM is currently overvalued and has a potential downside of -10.48%.
Roundhill GLP-1 Weight Loss has no consensus analysts rating.
According to ValueRays Forecast Model, OZEM Roundhill GLP-1 Weight Loss will be worth about 24 in March 2026. The stock is currently trading at 24.04. This means that the stock has a potential downside of -0.37%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24 | -0.4% |